HomeCompareHGENQ vs EPRT

HGENQ vs EPRT: Dividend Comparison 2026

HGENQ yields 1000000.00% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HGENQ wins by $4.7683925249533696e+36M in total portfolio value
10 years
HGENQ
HGENQ
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full HGENQ calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — HGENQ vs EPRT

📍 HGENQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHGENQEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HGENQ + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HGENQ pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HGENQ
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, HGENQ beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HGENQ + EPRT for your $10,000?

HGENQ: 50%EPRT: 50%
100% EPRT50/50100% HGENQ
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

HGENQ
Analyst Ratings
1
Buy
4
Hold
1
Sell
Consensus: Hold
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HGENQ buys
0
EPRT buys
0
No recent congressional trades found for HGENQ or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHGENQEPRT
Forward yield1000000.00%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$4.7683925249533696e+36M$64.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$13,170.85
Total dividends collected$4.7683311610149396e+36M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: HGENQ vs EPRT ($10,000, DRIP)

YearHGENQ PortfolioHGENQ Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,212$512.01+$100.00MHGENQ
2$934,786,450,701$934,679,439,252.34$12,689$692.09+$934786.44MHGENQ
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,521$944.30+$8165787108.56MHGENQ
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,841$1,302.88+$66665884190957.63MHGENQ
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$19,841$1,821.64+$508662171058048128.00MHGENQ
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$23,818$2,587.47+$3.62723524842849e+21MHGENQ
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$29,230$3,744.65+$2.417368115915061e+25MHGENQ
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$36,816$5,540.38+$1.5056740286145463e+29MHGENQ
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$47,806$8,413.17+$8.764771002818475e+32MHGENQ
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$64,324$13,170.85+$4.7683925249533696e+36MHGENQ

HGENQ vs EPRT: Complete Analysis 2026

HGENQStock

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full HGENQ Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this HGENQ vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HGENQ vs SCHDHGENQ vs JEPIHGENQ vs OHGENQ vs KOHGENQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.